| Bioactivity | LY300503 is an enantiomer of LY191704. LY191704 is a human type I 5α-reductase inhibitor[1][2]. |
| In Vivo | LY300503 (30-300 mg/kg; p.o. for 14 d) exhibits the mean dose-normalized AUC value of 56% after the first dose and 38% after the last dose in rats[2]. |
| Name | LY300503 |
| CAS | 148905-79-7 |
| Formula | C14H16ClNO |
| Molar Mass | 249.74 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Farid NA, et, al. High-performance liquid chromatographic determination of the enantiomers of the benzoquinolinone LY191704, a human type 1 5 alpha-reductase inhibitor, in plasma. J Chromatogr B Biomed Sci Appl. [2]. Farid NA, et, al. Stereoselective disposition of the enantiomers of the benzoquinolinone LY191704, a human type I 5 alpha-reductase inhibitor. Differences between rats and dogs. Drug Metab Dispos. 1996 Oct;24(10):1162-5. |